Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
| Revenue (TTM) | $1.45B |
| Gross Profit (TTM) | $979.97M |
| EBITDA | $203.96M |
| Operating Margin | 10.20% |
| Return on Equity | 12.70% |
| Return on Assets | 6.70% |
| Revenue/Share (TTM) | $37.20 |
| Book Value | $37.48 |
| Price-to-Book | 8.50 |
| Price-to-Sales (TTM) | 8.59 |
| EV/Revenue | 8.34 |
| EV/EBITDA | 54.82 |
| Quarterly Earnings Growth (YoY) | -18.00% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $39.33M |
| Float | $38.23M |
| % Insiders | 2.90% |
| % Institutions | 87.09% |
Volatility is currently contracting
ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally.
THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
